(4TEEN4 Pharmaceuticals GmbH) 4TEEN4 reports on the efficacy of Procizumab in a preclinical model of sepsis
(sphingotec GmbH) Endothelial dysfunction is driving pathophysiological processes such as congestion in heart failure, shock in sepsis, and lung dysfunction in COVID-19
IB10 sphingotest DPP3 is now available on sphingotec's proprietary automated Nexus IB10 point-of-care platform and quantitatively measures levels of circulating DPP3 in whole blood and plasma samplesData presented by Prof. Alexandre Mebazaa at ESC Congress 2019 in Paris provide evidence for a novel disease mechanism in which circulating DPP3 has a causal role in cardiac and renal dysfunctionFurther results presented by Prof. Mebazaa demonstrate that effects of pathological concentrations of DPP3 were immediately reversed in pre-clinical disease models upon injection of Procizumab, an anti-DPP3-antibody in preclinical development by 4TEEN4 Pharmaceuticalssphingotec has in-licensed global rights to distribute DPP3 on Nexus IB10 from 4TEEN4 Pharmaceuticals GmbH for diagnostic purposes in multiple indicationsThe novel DPP3 test complements sphingotec's portfolio of IVD tests for acute care biomarkers, including vascular function marker bio-ADM and kidney function marker penKid , designed to support decision making at ICUs and EDsParis, France, and Hennigsdorf/Berlin, Germany, August 31, 2019 - Diagnostics company SphingoTec GmbH ("sphingotec", Hennigsdorf near Berlin, Germany) today launched IB10 sphingotest DPP3, the first CE-IVD-marked point-of-care biomarker test able to quantify DPP3 blood-plasma levels, a novel and unique biomarker predicting outcomes in patients with cardiogenic shock at admission to intensive care units (ICUs).
Clinical data presented by Prof. Alexandre Mebazaa at ESC Congress 2019 in Paris provide evidence for a novel disease mechanism in which circulating DPP3 degrades central mediators of heart and kidney function, rapidly leading to fatal organ dysfunction.4TEEN4 Pharmaceuticals GmbH licensed its diagnostic biomarker test DPP3 to SphingoTec GmbH, which today launched the IB10 sphingotest DPP3 assay for use with the Nexus IB10 point-of-care analyser, the first CE-IVD test for DPP3.Paris, France, and Hennigsdorf/Berlin, Germany, August 31, 2019 - 4TEEN4 Pharmaceuticals GmbH ("4TEEN4", former Sphingotec Therapeutics GmbH, Hennigsdorf/Berlin, Germany) today for the first time reported preclinical data on its lead product Procizumab, a therapeutic antibody targeting circulating Dipeptidyl Peptidase 3 (DPP3) for the treatment of patients with acute myocardial depression including acute heart failure and cardiogenic shock.The published data further emphasizes the medical utility of DPP3 as a biomarker predicting organ dysfunction and outcome in critically ill patients."Procizumab is a novel treatment approach targeting a recently identified DPP3-mediated disease mechanism in critically ill patients", said Prof. Mebazaa, whose results were also published today in the European Journal of Heart Failure5,6.Supported by excellent clinical cohort results on the DPP3 biomarker, we are now preparing for first-in-men clinical trials" said Dr. Andreas Bergmann, CEO of 4TEEN4.
Data from more than 20,000 patients show that bio-ADM adds value to clinical decision-making at ICUs and EDs because it is the only biomarker that allows early prediction of septic shockbio-ADM allows starting life-saving interventions such as early administration of vasopressors which will benefit about 20% of sepsis patientsbioADM is used for patient selection in an ongoing phase II trial with therapeutic antibody Adrecizumabbio-ADM POC test for rapid decision-making at ICUs and EDs will be launched by H1/2019Hennigsdorf/Berlin - Diagnostics company sphingotec GmbH reports novel applications of bio-ADM (bio-active adrenomedullin), the very first biomarker capable to diagnose the onset of septic shock, allowing physicians earliest life-saving therapeutic interventions in sepsis critical care.At the 39th International Symposium on Intensive Care and Emergency Medicine (ISICEM, 19-22 March, 2019, Brussels), Prof Peter Pickkers (Radbound umc Nijmegen, The Netherlands) will report that bio-ADM is used to select patients at high risk for septic shock for treatment with the antibody Adrecizumab (Adrenomed AG, Hennigsdorf, Germany), which is being evaluated in an ongoing Phase II study on patients with early septic shock.